Dual CARCIK Strategy Enters Early Testing in High-Risk AML and BPDCN
A phase 1/2 study is preparing to test CARCIK-CD123/33 cells in children and adults with relapsed or refractory acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm who have run out of standard options. The trial is designed around a hard clinical problem: persistent leukemia that has already resisted multiple treatment lines, including disease that has returned after allogeneic hematopoietic cell transplantation. In that setting, the therapeutic goal shifts from chasing durable remission with conventional chemotherapy alone to using engineered immune cells to reduce disease burden before a planned transplant.
The study, NCT07877610, is an interventional phase 1/2 program with an estimated enrollment of 18 participants. It is being conducted in Italy at two sites, with one location in Bergamo and another in Monza. The design includes both pediatric and adult patients, spanning children as young as 6 months and adults up to 75 years old. The broad age range signals an attempt to explore whether a single dual-target cellular platform can be delivered across very different immune, marrow, and transplant contexts.
Why CD123 and CD33 Matter in Resistant Myeloid Disease
The biologic rationale is straightforward. CD123 and CD33 are antigens expressed on leukemic blasts in a range of myeloid malignancies, and the protocol requires confirmed expression of both markers by flow cytometry. Targeting two antigens instead of one is meant to reduce the risk that a leukemic clone escapes treatment by downregulating a single surface marker. In refractory disease, antigen heterogeneity is not a theoretical concern; it is one of the reasons single-target immunotherapies can fail after an initial response.
This trial uses a nonviral allogeneic CARCIK platform. By relying on donor-derived cells rather than autologous collection from heavily pretreated patients, the approach may be better suited to individuals whose marrow reserve, prior therapies, or rapidly progressing disease would make traditional cell manufacturing difficult. The protocol also frames treatment as a bridge toward subsequent allogeneic transplantation, which is clinically important because transplant remains one of the few curative options for a subset of these patients.
The trial title and overview make clear that investigators are not starting from a broad leukemia population. Eligibility is narrow and intentionally high risk: active disease with marrow and/or peripheral blood involvement, no curative option using currently available therapy, or relapse after allogeneic transplant. Patients can enter with persistent molecular, phenotypic, or cytogenetic disease after transplant, including measurable residual disease detected by flow cytometry greater than 1%. That inclusion detail matters because it captures relapse biology before overt morphologic resurgence in some patients, when tumor burden may still be low enough for cellular therapy to have a meaningful chance of exerting control.
Trial Entry Conditions Reflect the Demands of Cellular Therapy
Enrollment requires an available haploidentical family member or unrelated donor willing and eligible to provide blood or lymphocyte material for CARCIK production. Patients also need a separate hematopoietic cell transplant donor, including the possibility of umbilical cord blood, and they must be considered eligible for a later alloHCT. In practical terms, the study is built for patients who can move through a sequence of interventions: donor cell production, infusion of CARCIK cells, and then transplant if disease control allows it.
Performance status and organ function requirements are conventional but consequential. Adults must have an Eastern Cooperative Oncology Group performance status of 2 or less, while younger children need a Lansky score above 50. Cardiac function must be adequate, with ejection fraction above 40%. Liver and renal thresholds are also specified, including bilirubin limits, transaminase limits, and renal cutoffs that differ for adults and children. These conditions help explain the clinical population the trial is willing to treat: medically fragile patients, but not those in whom major organ dysfunction would make a complex immunotherapy sequence unsafe or uninterpretable.
One sentence captures the narrowness of the eligible population: this is not a salvage study for any relapsed leukemia, but for patients whose disease remains biologically targetable and whose bodies can still tolerate the transplant pathway.
Safety Guardrails Center on Infection and Reproductive Risk
The exclusion criteria begin with active clinically significant viral, bacterial, or fungal infection. Active hepatitis B, active hepatitis C, and HIV positivity are also exclusions, although the protocol allows certain treated hepatitis B and cured hepatitis C scenarios under specific viral-load and timing conditions. Those restrictions are predictable in a study built around immune effector cells and subsequent transplant, where uncontrolled infection could blur toxicity signals or produce unacceptable risk.
Reproductive precautions are extensive. Females of childbearing potential must have a negative pregnancy test, commit to abstinence or effective contraception, and continue those measures for at least 12 months after infusion and until CAR-positive viable T cells are no longer detected on two consecutive qPCR tests. Male participants face parallel requirements, including abstinence or condom use for the same post-infusion window. The long duration reflects the persistence investigators are anticipating from infused engineered cells and the desire to prevent any theoretical fetal exposure during the period when CAR-positive cells may still be present.
A Small Early-Phase Study With Large Questions Ahead
This is an early-phase trial, and no outcomes have been posted. The study start is estimated for October 2026, with primary completion estimated for October 2028 and final study completion in October 2029. Until data emerge, the most important unknowns remain clinical rather than logistical: whether the dual-target CARCIK construct can be manufactured reliably, whether it can be infused safely into heavily pretreated children and adults, and whether it can produce enough cytoreduction to create a meaningful bridge to alloHCT.
The design choice to include both AML and BPDCN reflects the shared antigenic territory between these diseases, but it also raises a real biological test. Myeloid neoplasms are notoriously adaptive, and a dual-target platform will need to show that it can suppress resistant clones without introducing prohibitive toxicity or failing under antigen pressure. The absence of results means the field has only the blueprint for now. The first meaningful readout will be whether this allogeneic CD123/CD33 approach can clear enough disease to justify the transplant sequence that follows.